Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer

Table 1

Overview of frequently used histone deacetylase inhibitors that are available for clinical and research purposes.

Substance groups	Derivatives	Isotype
Hydroxamates	Trichostatin A (TSA)	I, II
	Suberoylanilide hydroxamic acid (SAHA, vorinostat)	I, II, IV
	LBH589 (panobinostat)	I, II, IV
	PCI24781 (CRA-024781)	I, IIb
	LAQ824	I, II
	PXD101 (belinostat)	I, II, IV
	ITF2357	I, II
	SB939	Unknown
	JNJ-16241199 (R306465)	I
	m-carboxycinnamic acid bishydroxamide (CBHA)
	Scriptaid
	Oxamflatin
	Pyroxamide
	Cyclic hydroxamic acid containing peptides (CHAPs)
Short chain fatty acids	Butyrate	I, IIa
	Valproate	I, IIa
	AN-9
	OSU-HDAC42
Benzamides	MS-275 (entinostat)	1, 2, 3, 9
	MGCD0103	1, 2, 3, 11
	Pimelic diphenylamide	1, 2, 3
	M344
	N-acetyldinaline (CI-994)
Cyclic tetrapeptides	Apicidine	I, II
	Trapoxins
	HC-toxin
	Chlamydocin
	Depsipeptide (FR901228 or FK228) (romidepsin)	1, 2, 4, 6
Sulfonamide anilides	N-2-aminophenyl-3-[4-(4-methylbenzenesulfonylamino)-phenyl]-2-propenamide
Others	Depudecin
	NDH-51
	KD5150	Pan-HDACI

Class I: HDAC1, -2, -3 and -8; class IIa: HDAC4, -5, -7, and -9; class IIb: HDAC 6, and -10; class III: SIRT1-7; class IV: HDAC11.